Nls pharmaceutics and kadimastem announce the submission of a request by kadimastem and itolerance, inc. for an fda pre-ind meeting for an innovative breakthrough type 1 diabetes treatment

This submission comes after successful interact meeting with the fda earlier this year. nls pharmaceutics and kadimastem working to close merger by the end of january 2025 zurich, switzerland and ness ziona, israel / accesswire / december 19, 2024 / nls pharmaceutics ltd.

NLSP Ratings Summary

NLSP Quant Ranking